Previous 10 | Next 10 |
The following slide deck was published by Corbus Pharmaceuticals Holdings, Inc. in conjunction with this event. For further details see: Corbus Pharmaceuticals (CRBP) Investor Presentation - Slideshow
Dogecoin (CRYPTO: DOGE) is the perfect tool for people who love casinos. With its rocket ship-style price movements and nary a fundamental factor tethering the cryptocurrency to any price, investors don't need to worry about complicated stuff like corporate earnings, macroeconomic c...
Vertex Energy (VTNR) +28%.Cloudera CLDR +24% on being acquired by Clayton, Dubilier & Rice and KKR for $5.3 billion.Orbsat Corp Common Stock (OSAT) +19%.AMC Entertainment Holdings AMC +16% on raising $230.0 million.Lineage Cell Therapeutics LCTX +14% on updat...
Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ High potency anti-αvβ8 mAb licensed from University of California San Francisco and anti-αvβ6/αvβ8 ...
Reddit Biotech Penny Stocks Remain in Focus in June 2021 Finding penny stocks on Reddit has become a major strategy for all types of investors. While Reddit hasn’t always been the place to find and make a penny stocks watchlist , it is more popular than ever. While there are ...
Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announc...
Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals H o ldings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocan...
Corbus Pharmaceuticals (CRBP): Q1 GAAP EPS of -$0.14 in-line.Revenue of $0.65M (-63.1% Y/Y) misses by $0.11M.Cash, cash equivalents and investments were $125 million as of March 31, 2021. During the first quarter of 2021, the Company raised $58.9 million in net proceeds from the Companyȁ...
Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022 Corbus is actively engaging with potential partners to expand ...
Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announc...
News, Short Squeeze, Breakout and More Instantly...
Corbus Pharmaceuticals Holdings Inc. Company Name:
CRBP Stock Symbol:
NASDAQ Market:
2024-05-13 06:15:04 ET RBC Capital analyst issues OUTPERFORM recommendation for CRBP on May 13, 2024 04:48AM ET. CRBP was trading at $42.99 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommen...
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor me...
Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIR...